GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arix Bioscience PLC (LSE:ARIX) » Definitions » Net Income From Continuing Operations

Arix Bioscience (LSE:ARIX) Net Income From Continuing Operations : £14.86 Mil (TTM As of Jun. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Arix Bioscience Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Arix Bioscience's net income from continuing operations for the six months ended in Jun. 2023 was £12.48 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2023 was £14.86 Mil.

Arix Bioscience Net Income From Continuing Operations Historical Data

The historical data trend for Arix Bioscience's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arix Bioscience Net Income From Continuing Operations Chart

Arix Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Income From Continuing Operations
Get a 7-Day Free Trial 42.76 -75.57 126.30 -61.08 -27.58

Arix Bioscience Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -38.46 -22.62 -29.96 2.38 12.48

Arix Bioscience Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £14.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arix Bioscience (LSE:ARIX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arix Bioscience PLC (LSE:ARIX) » Definitions » Net Income From Continuing Operations
Comparable Companies
LSE:HVO LSE:FARN LSE:BVXP LSE:SCLP LSE:OXB LSE:FUM LSE:REDX LSE:OBD LSE:4BB LSE:ETX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
50 Duke Street, Duke Street House, London, GBR, W1K 6JL
Website
https://www.arixbioscience.com
Arix Bioscience PLC is a healthcare and life science company. Its business model is to source, finance, and develop healthcare and life science businesses that deliver or seek to deliver therapies to patients. Its segment includes sourcing, financing, and developing healthcare and life science businesses globally.

Arix Bioscience (LSE:ARIX) Headlines

No Headlines